Repurposed Antiparasitic Drugs in Oncology: A Landscape Overview
Overview of antiparasitic drugs studied for anti-cancer properties: fenbendazole, mebendazole, ivermectin, niclosamide, and the repurposing landscape.
March 8, 2026 No Comments
Overview of antiparasitic drugs studied for anti-cancer properties: fenbendazole, mebendazole, ivermectin, niclosamide, and the repurposing landscape.
Emerging research on fenbendazole and breast cancer: cell cycle arrest, apoptosis induction, and p53-dependent mechanisms in laboratory models.
Preclinical research on combining fenbendazole with conventional chemotherapy: synergistic effects and how benzimidazoles may enhance standard treatments.
How ivermectin targets cancer through autophagy, Wnt signaling inhibition, and tumor microenvironment remodeling — preclinical and clinical data.
Laboratory evidence on fenbendazole’s effects against colorectal cancer cells: key in vitro studies, mechanisms of action, and preclinical data.
Why fat-soluble formulations matter for fenbendazole absorption: dissolution effects, pharmacokinetic data, and practical tips to improve uptake.
How nanoparticle delivery technology may improve fenbendazole effectiveness: encapsulated formulations, enhanced bioavailability, and targeted delivery.
Research on mebendazole as a repurposed therapy for thyroid cancer: in vitro evidence and mechanisms targeting papillary and anaplastic subtypes.
Independent investigation into Fenben Lab’s product quality: self-issued certificates, lab testing transparency, and what consumers should know.